Search our website

Sci-B-Vac®

VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
February 2nd, 2021
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
January 15th, 2021
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine
December 23rd, 2020
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
December 7th, 2020
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
December 2nd, 2020
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
December 1st, 2020
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
November 23rd, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
November 13th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
October 26th, 2020
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 15th, 2020
VBI Vaccines Announces e-Poster Presentation at The Liver Meeting® 2020
October 8th, 2020
VBI Vaccines to Present at Upcoming Scientific Conferences
September 24th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020
August 31st, 2020
VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral and Poster Presentations at EASL 2020
August 20th, 2020
VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints
January 9th, 2020
VBI Vaccines Announces Late-Breaker Poster Presentation at The Liver Meeting® 2019
October 22nd, 2019
VBI Vaccines Announces Late-Breaker Oral Presentation at IDWeek 2019™
October 2nd, 2019
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
June 17th, 2019
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16th, 2019
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
April 17th, 2019

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top